NCT05625542 (CKD) is a clinical trial in Chronic Kidney Disease-associated Pruritus, sponsored by Vifor (International) Inc..

Who is sponsoring NCT05625542?

NCT05625542 is sponsored by Vifor (International) Inc..

What condition does NCT05625542 study?

NCT05625542 studies Chronic Kidney Disease-associated Pruritus.

Is NCT05625542 still recruiting?

NCT05625542 is currently withdrawn. Last updated 5 July 2023.

Last reviewed 2023-07-05 · How we verify

NCT05625542: CKD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients

Withdrawn Last updated 5 July 2023

What this trial tests

trial in Chronic Kidney Disease-associated Pruritus. Withdrawn.

Timeline

10 June 2023

Primary endpoint
10 June 2023

30 June 2023

Quick facts

Lead sponsor	Vifor (International) Inc.
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	10 June 2023
Primary completion	10 June 2023
Estimated completion	30 June 2023

Conditions studied

Chronic Kidney Disease-associated Pruritus — all drugs for Chronic Kidney Disease-associated Pruritus →

Sponsor

Vifor (International) Inc. — full company profile →

Who can join

18 and older, any sex, with Chronic Kidney Disease-associated Pruritus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vifor International Ltd. is seeking real-world evidence (RWE) to better understand the epidemiology, patient characteristics, and management of CKD-aP in the real-world clinical setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Vifor (International) Inc. trials

Trials by the same sponsor.

NCT05524467 — Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients · completed
NCT05460234 — RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients · completed
NCT04817670 — Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease · Phase 2 · completed
NCT05077436 — Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects · Phase 1 · completed
NCT04864795 — Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05625542 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vifor (International) Inc.
Last refreshed: 5 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05625542.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing